Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer

[1]  A. Schneeweiss,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Luini,et al.  Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  G. Hortobagyi,et al.  Inflammatory breast cancer (IBC) and patterns of recurrence , 2007, Cancer.

[4]  A. Luini,et al.  Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer , 2007, British Journal of Cancer.

[5]  C. Sotiriou,et al.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients , 2007, British Journal of Cancer.

[6]  W. Holzgreve,et al.  Non‐inflammatory skin involvement in breast cancer, histologically proven but without the clinical and histological T4 category features , 2007, Journal of surgical oncology.

[7]  Andreas Makris,et al.  Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer , 2006, Breast Cancer Research.

[8]  Andreas Makris,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. Akiyama,et al.  High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer , 2006, Breast cancer.

[10]  L. Carey,et al.  Size of Residual Lymph Node Metastasis After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients Is Prognostic , 2006, Annals of Surgical Oncology.

[11]  G. Hortobagyi,et al.  Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Hortobagyi,et al.  Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[13]  S. Steinberg,et al.  Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Dowsett,et al.  Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer , 2003, British Journal of Cancer.

[15]  W. Anderson,et al.  Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Aas,et al.  Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. , 2003, European journal of cancer.

[17]  R. Gelber,et al.  Ki‐67 expression in breast carcinoma , 2003, Cancer.

[18]  M. Espié,et al.  Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer , 2002, Oncogene.

[19]  Donald L Weaver,et al.  Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Gelber,et al.  Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Bruzzi,et al.  Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer , 2001, British Journal of Cancer.

[22]  T. Powles,et al.  Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma , 2000, Cancer.

[23]  M. J. van de Vijver,et al.  Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial , 2000, Cancer.

[24]  M. J. van de Vijver,et al.  The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[25]  A. Goldhirsch,et al.  Prediction of response to primary chemotherapy for operable breast cancer. , 1999, European journal of cancer.

[26]  G. Hortobagyi,et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Arends,et al.  MIB-1 labelling index is an independent prognostic marker in primary breast cancer. , 1998, British Journal of Cancer.

[28]  C. Elston,et al.  Disease of the breast , 1998 .

[29]  G. Hortobagyi,et al.  Ki‐67 immunostaining in node‐negative stage I/II breast carcinoma. Significant correlation with prognosis , 1991, Cancer.

[30]  C. Carter,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989, Cancer.

[31]  D. Berry.  Chemotherapy is More Effective in Patients With Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment , 2006 .

[32]  V. Kosma,et al.  The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[33]  T. Powles,et al.  Prognostic relavance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy , 2004, Breast Cancer Research and Treatment.

[34]  A. Ezzat,et al.  HER-2/Neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer , 2002, Medical oncology.

[35]  R. Love.  Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[37]  M. Osborn,et al.  Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  M. Lippman,et al.  Lack of estrogen receptor associated with an increased response rate to cytotoxic chemotherapy in metastatic breast cancer? , 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.